Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 11/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5607299 | 0.94 | LCK (0.59) | LCKLMNANPC1MAPTRAB9A | |
| SCHEMBL774952 | 0.85 | LCK (0.76) | LCK | |
| SCHEMBL5607542 | 0.84 | LCK (0.71) | LCK | |
| SCHEMBL774457 | 0.82 | LCK (0.72) | LCKLMNAKMT2ANPC1MAPT | |
| SCHEMBL771915 | 0.80 | LCK (0.82) | LCK | |
| SCHEMBL6604812 | 0.79 | LCK (0.83) | LCKLMNAHTTALDH1A1 | |
| SCHEMBL774205 | 0.78 | MAPT (0.81) | LCKLMNAKMT2ANPC1MAPT | |
| SCHEMBL5608019 | 0.78 | LCK (0.52) | LCKLMNAKMT2ANPC1MAPT | |
| SCHEMBL774344 | 0.78 | LCK (0.60) | LCKLMNAKMT2ANPC1RAB9A | |
| SCHEMBL5608233 | 0.77 | CHRNA7 (0.64) | LCKKMT2AMAPTALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1758564-A2 | SYNERGISTIC METHODS AND COMPOSITIONS FOR TREATING CANCER | Brystol-Myers Squibb Company (US) | 2007-03-07 | — | — | EP | claimed |
| WO-2005094376-A2 | SYNERGISTIC METHODS AND COMPOSITIONS FOR TREATING CANCER | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-10-13 | — | — | WO | claimed |
| EP-1758564-A2 | SYNERGISTIC METHODS AND COMPOSITIONS FOR TREATING CANCER | Brystol-Myers Squibb Company (US) | 2007-03-07 | — | — | EP | disclosed |
| WO-2005094376-A2 | SYNERGISTIC METHODS AND COMPOSITIONS FOR TREATING CANCER | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-10-13 | — | — | WO | disclosed |